Cogent Q3 Loss Widens to $111M as Three FDA Decisions Loom
COGT has more than doubled off its 52-week low of $13.78.
Summary
Cogent's Q3 net loss widened to $111.4 million from $96.4 million in Q2, with operating expenses of $117.2 million as it funds the SUMMIT, PEAK and APEX trials and builds out commercial readiness. The cash pile of $791.1 million is roughly flat versus the $792.3 million reported at Q2 and management says it funds operations into late 2028. The real story is the approval calendar: bezuclastinib could get an FDA nod in GIST by Nov. 30, 2026, in NonAdvSM by Dec. 30, 2026, and in AdvSM by June 29, 2027 — three shots on goal inside about 18 months. The loss itself is the expected cost of that ramp, not a surprise, so the stock reaction should hinge on the GIST decision due within weeks.
At the time of this announcement, COGT was trading at $29.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.1B. The 52-week trading range was $13.78 to $43.73. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.